To further expand previous findings, we evaluated the metabolic characteristics and the effects of 2-DG- and mannose-treatments in other PDAC cancer cell lines characterized by expression of oncogenic KRAS, namely PANC-1 (G12D), SU.86.86 (G12D), and Capan-1 (G12V), and derived either from primary tumor (PANC-1) or from metastasis (SU86.86 and Capan-1). This evidence concerns the gene KRAS and cancer.